O. Christensen

发表

A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

Martin Büchert, Ulrike Fasol, Oliver Boix, 2012, Clinical Cancer Research.

Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.

M. Piccart-Gebhart, M. Radtke, C. Lathia, 2012, European journal of cancer.

Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial.

D. Strumberg, R. Hilger, H. Richly, 2009, European journal of cancer.

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors.

D. Strumberg, S. Seeber, R. Hilger, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

J. Schlom, R. Madan, J. Marté, 2018, Clinical Cancer Research.

Phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in advanced solid tumors

Zhigang, Kang, J. Schlom, 2017 .

UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib

Soma Das, M. Sawyer, Q. Chu, 2009, Cancer Chemotherapy and Pharmacology.

Phase I study of BAY 43-9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors

B. Schwartz, E. Brendel, K. Mross, 2005 .

Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors.

A. Tolcher, Toshio Shimizu, K. Papadopoulos, 2010 .

Phase I study of BAY 57-9352, a VEGFR-2 inhibitor, in cycles of 14 days on/7 days off in patients with advanced solid tumors.

D. Strumberg, M. Scheulen, D. Voliotis, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032

D. Jäger, P. Ascierto, P. Ott, 2015, Journal of Immunotherapy for Cancer.

Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.

P. Ascierto, P. Sharma, P. Ott, 2016 .

Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer.

D. Strumberg, R. Hilger, B. Schwartz, 2004, International journal of clinical pharmacology and therapeutics.

Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors.

P. Sharma, P. Ott, M. Callahan, 2014 .

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

D. Strumberg, S. Seeber, D. Voliotis, 2006, European journal of cancer.

Abstract 1666: Regorafenib (BAY 73-4506): preclinical pharmacology and clinical identification and quantification of its major metabolites

D. Zopf, K. Thierauch, S. Wilhelm, 2010 .

Phase I study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced refractory colorectal carcinoma (CRC).

M. Büchert, D. Strumberg, M. Scheulen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.

J. Schellens, E. Voest, H. Verheul, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

D. Jäger, P. Ascierto, P. Sharma, 2016, The Lancet. Oncology.

Quantification of vascular endothelial growth factor, interleukin-8, and basic fibroblast growth factor in plasma of cancer patients and healthy volunteers – comparison of ELISA and microsphere-based multiplexed immunoassay

G. Wensing, M. Kornacker, J. Krätzschmar, 2008, Clinical chemistry and laboratory medicine.

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

M Büchert, M Jeffers, M. Büchert, 2012, British Journal of Cancer.

Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC).

A. Tolcher, M. Kies, G. Blumenschein, 2010 .

Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.

C. Unger, M. Radtke, E. Brendel, 2007, European journal of cancer.

Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer.

D. Strumberg, S. Seeber, R. Hilger, 2005, Clinical colorectal cancer.

Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor

H. Putter, T. Rabelink, E. D. de Koning, 2008, Clinical Cancer Research.

Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

J. Bloem, J. Verweij, J. Nortier, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours

D. Strumberg, M. Scheulen, P. Rajagopalan, 2008, British Journal of Cancer.

Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer

M. Büchert, D. Strumberg, M. Scheulen, 2011, Vascular cell.

Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.

P. Ascierto, P. Ott, M. Pietanza, 2015 .

Preliminary results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in advanced solid tumors.

J. Schlom, R. Madan, J. Marté, 2017 .

VEGFR2 blockade in patients with solid tumors: Mechanism of hypertension and effects on vascular function.

H. Gelderblom, N. Steeghs, O. Christensen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of BAY 73–4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors: Final results of a dose-escalation study

C. Unger, D. Strumberg, M. Scheulen, 2008 .

Phase I study of BAY 73-4506, a multikinase inhibitor, administered for 21 days on/7 days off in patients with advanced solid tumors

M. Büchert, C. Unger, D. Voliotis, 2007 .

72 POSTER Phase I, safety, pharmacokinetic and biomarker study of telatinib (BAY 57-9352), an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors

J. Verweij, H. Gelderblom, P. Rajagopalan, 2006 .

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

D. Jäger, P. Ascierto, P. Sharma, 2016, The Lancet. Oncology.